Courtney Tindle1,2, MacKenzie Fuller1,2, Ayden Fonseca1,2, Sahar Taheri3, Pradipta Ghosh1,2,4, Soumita Das2,5, Stella-Rita Ibeawuchi5, Nathan Beutler6, Gajanan Dattatray Katkar1, Amanraj Claire1,2, Vanessa Castillo1, Moises Hernandez7, Hana Russo5, Jason Duran8, Laura E Crotty Alexander9,10, Ann Tipps5, Grace Lin5, Patricia A Thistlethwaite7, Ranajoy Chattopadhyay1,2,11, Thomas F Rogers6,12,6, Debashis Sahoo3,13. 1. Department of Cellular and Molecular Medicine, University of California San Diego, San Diego, United States. 2. HUMANOID CoRE, University of California San Diego, San Diego, United States. 3. Department of Computer Science and Engineering, Jacobs School of Engineering, University of California San Diego, San Diego, United States. 4. Department of Medicine, University of California, San Diego, La Jolla, CA, United States. 5. Department of Pathology, University of California San Diego, San Diego, United States. 6. Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, United States. 7. Division of Cardiothoracic Surgery, University of California San Diego, San Diego, United States. 8. Division of Cardiology, Department of Internal Medicine, UC San Diego Medical Center, San Diego, United States. 9. Pulmonary Critical Care Section, Veterans Affairs (VA) San Diego Healthcare System, La Jolla, United States. 10. Division of Pulmonary and Critical Care, Department of Medicine, University of California, San Diego, La Jolla, CA, United States. 11. Cell Applications Inc., La Jolla, CA, United States. 12. Division of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, United States. 13. Department of Pediatrics, University of California, San Diego, La Jolla, CA, United States.
Abstract
Background: SARS-CoV-2, the virus responsible for COVID-19, causes widespread damage in the lungs in the setting of an overzealous immune response whose origin remains unclear. Methods: We present a scalable, propagable, personalized, cost-effective adult stem cell-derived human lung organoid model that is complete with both proximal and distal airway epithelia. Monolayers derived from adult lung organoids (ALOs), primary airway cells, or hiPSC-derived alveolar type II (AT2) pneumocytes were infected with SARS-CoV-2 to create in vitro lung models of COVID-19. Results: Infected ALO monolayers best recapitulated the transcriptomic signatures in diverse cohorts of COVID-19 patient-derived respiratory samples. The airway (proximal) cells were critical for sustained viral infection, whereas distal alveolar differentiation (AT2→AT1) was critical for mounting the overzealous host immune response in fatal disease; ALO monolayers with well-mixed proximodistal airway components recapitulated both. Conclusions: Findings validate a human lung model of COVID-19, which can be immediately utilized to investigate COVID-19 pathogenesis and vet new therapies and vaccines. Funding: This work was supported by the National Institutes for Health (NIH) grants 1R01DK107585-01A1, 3R01DK107585-05S1 (to SD); R01-AI141630, CA100768 and CA160911 (to PG) and R01-AI 155696 (to PG, DS and SD); R00-CA151673 and R01-GM138385 (to DS), R01- HL32225 (to PT), UCOP-R00RG2642 (to SD and PG), UCOP-R01RG3780 (to P.G. and D.S) and a pilot award from the Sanford Stem Cell Clinical Center at UC San Diego Health (P.G, S.D, D.S). GDK was supported through The American Association of Immunologists Intersect Fellowship Program for Computational Scientists and Immunologists. L.C.A's salary was supported in part by the VA San Diego Healthcare System. This manuscript includes data generated at the UC San Diego Institute of Genomic Medicine (IGC) using an Illumina NovaSeq 6000 that was purchased with funding from a National Institutes of Health SIG grant (#S10 OD026929).
Background: SARS-CoV-2, the virus responsible for COVID-19, causes widespread damage in the lungs in the setting of an overzealous immune response whose origin remains unclear. Methods: We present a scalable, propagable, personalized, cost-effective adult stem cell-derived human lung organoid model that is complete with both proximal and distal airway epithelia. Monolayers derived from adult lung organoids (ALOs), primary airway cells, or hiPSC-derived alveolar type II (AT2) pneumocytes were infected with SARS-CoV-2 to create in vitro lung models of COVID-19. Results: Infected ALO monolayers best recapitulated the transcriptomic signatures in diverse cohorts of COVID-19 patient-derived respiratory samples. The airway (proximal) cells were critical for sustained viral infection, whereas distal alveolar differentiation (AT2→AT1) was critical for mounting the overzealous host immune response in fatal disease; ALO monolayers with well-mixed proximodistal airway components recapitulated both. Conclusions: Findings validate a human lung model of COVID-19, which can be immediately utilized to investigate COVID-19 pathogenesis and vet new therapies and vaccines. Funding: This work was supported by the National Institutes for Health (NIH) grants 1R01DK107585-01A1, 3R01DK107585-05S1 (to SD); R01-AI141630, CA100768 and CA160911 (to PG) and R01-AI 155696 (to PG, DS and SD); R00-CA151673 and R01-GM138385 (to DS), R01- HL32225 (to PT), UCOP-R00RG2642 (to SD and PG), UCOP-R01RG3780 (to P.G. and D.S) and a pilot award from the Sanford Stem Cell Clinical Center at UC San Diego Health (P.G, S.D, D.S). GDK was supported through The American Association of Immunologists Intersect Fellowship Program for Computational Scientists and Immunologists. L.C.A's salary was supported in part by the VA San Diego Healthcare System. This manuscript includes data generated at the UC San Diego Institute of Genomic Medicine (IGC) using an Illumina NovaSeq 6000 that was purchased with funding from a National Institutes of Health SIG grant (#S10 OD026929).
Authors: Jhansi L Leslie; Sha Huang; Judith S Opp; Melinda S Nagy; Masayuki Kobayashi; Vincent B Young; Jason R Spence Journal: Infect Immun Date: 2014-10-13 Impact factor: 3.441
Authors: Anja C Roden; Melanie C Bois; Tucker F Johnson; Marie Christine Aubry; Mariam P Alexander; Catherine E Hagen; Peter T Lin; Reade A Quinton; Joseph J Maleszewski; Jennifer M Boland Journal: Arch Pathol Lab Med Date: 2021-01-01 Impact factor: 5.534
Authors: Piero Dalerba; Tomer Kalisky; Debashis Sahoo; Pradeep S Rajendran; Michael E Rothenberg; Anne A Leyrat; Sopheak Sim; Jennifer Okamoto; Darius M Johnston; Dalong Qian; Maider Zabala; Janet Bueno; Norma F Neff; Jianbin Wang; Andrew A Shelton; Brendan Visser; Shigeo Hisamori; Yohei Shimono; Marc van de Wetering; Hans Clevers; Michael F Clarke; Stephen R Quake Journal: Nat Biotechnol Date: 2011-11-13 Impact factor: 54.908
Authors: Kenrie P Y Hui; Man-Chun Cheung; Ranawaka A P M Perera; Ka-Chun Ng; Christine H T Bui; John C W Ho; Mandy M T Ng; Denise I T Kuok; Kendrick C Shih; Sai-Wah Tsao; Leo L M Poon; Malik Peiris; John M Nicholls; Michael C W Chan Journal: Lancet Respir Med Date: 2020-05-07 Impact factor: 30.700
Authors: Michael A Bukys; Alexander Mihas; Krystal Finney; Katie Sears; Divya Trivedi; Yong Wang; Jose Oberholzer; Jan Jensen Journal: iScience Date: 2020-07-04